Lv22
180 积分 2026-05-13 加入
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
25天前
已完结
Targeting Solid Tumors Using CD3 Bispecific Antibodies
1个月前
已完结
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
1个月前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
2个月前
已完结
Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression
3个月前
已关闭
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
3个月前
已完结
Metronomic oral cyclophosphamide & low dose nivolumab for advanced hepatocellular carcinoma (HCC)
3个月前
已关闭
Clinical Characteristics and Prognosis of Hepatocellular Carcinoma
4个月前
已完结
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
4个月前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
4个月前
已完结
皖公网安备34019202002308
